73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
B Syncona Ltd
B
Closed
93 2.54
Overview
Share price change
24h
Min
89.6
Max
93.8
Income | -68M |
|---|---|
Sales | 44M |
Profit margin | -153.576 |
Employees | 1,215 |
EBITDA | -49M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +105.43% upside |
Market Cap | 556M |
|---|---|
Previous open | 90.46 |
Previous close | 93 |
Syncona Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Syncona Ltd Forecast
Price Target
By TipRanks
105.43% upside
12 Months Forecast
Average 189 GBX 105.43%
High 189 GBX
Low 189 GBX
Based on 1 Wall Street analysts offering 12 month price targets forSyncona Ltd - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
EBITDA
Operating profit
$
About Syncona Ltd
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
Live chat